American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting最新文献

{"title":"The Art of Oncology Education and Knowledge Sharing-It is All About the \"How\".","authors":"Guilherme Sacchi de Camargo Correia, Lori J Rosenstein, Rohit Gosain, Rami Manochakian","doi":"10.1200/EDBK-25-471836","DOIUrl":"https://doi.org/10.1200/EDBK-25-471836","url":null,"abstract":"<p><p>In the rapidly evolving field of oncology, education and knowledge sharing have become essential aspects of oncology practice and must-needed tools to help patients conquer cancer. Oncology education is an art that needs to be mastered by applying scientific learning methods through structured frameworks into it, in order to have an impact. To effectively educate and share knowledge with oncology professionals, we propose following a \"chain of education\". This chain consists of five links that are essential for creating a successful educational activity: \"who\", \"why\", \"where\", \"what\", and \"how\". By following the \"chain of education\" through all links leading to the final key of how to educate, and guided by learning science principles, educators can optimize and enhance their teaching and knowledge-sharing skills and educate learners with more impact. Two common scenarios of medical education in oncology are the education of trainees and the education of community oncologists. In this article, we review them through the prism of the \"chain of education\". We discuss how using effective learning science principles can guide small changes that lead to significant impacts in trainees' education and can also leverage social media platforms in the education of community oncologists. Alongside this described framework, we briefly review some available oncology education resources, and we discuss incorporating the \"chain of education\" into future technologies.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e471836"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incorporating Targeted Therapy Into Neuro-Oncology Practice.","authors":"Marjolein Geurts, Juan B Blaquier, Maarten Wijnenga, David O Kamson, Macarena I de la Fuente","doi":"10.1200/EDBK-25-473324","DOIUrl":"https://doi.org/10.1200/EDBK-25-473324","url":null,"abstract":"<p><p>The integration of targeted therapies into neuro-oncology is revolutionizing the management of primary CNS malignancies. Advances in sequencing technologies and the incorporation of molecular alterations into CNS tumor classification have led to more precise tumor prognosis and enabled the identification of actionable oncogenic drivers. However, challenges such as drug delivery, tumor and microenvironment heterogeneity, and limitations of preclinical models complicate the selection of effective therapies. This review presents a comprehensive framework for optimizing drug selection in neuro-oncology. We discuss strategies to enhance drug development and improve clinical trial success, including window-of-opportunity trials and advanced imaging techniques. Additionally, we highlight recent advances in the treatment of isocitrate dehydrogenase-mutant gliomas, focusing on the INDIGO study and its role in the regulatory approval of vorasidenib. The review also examines the use of MAPK inhibitors, from BRAF inhibitors to PAN-RAF inhibitors, in both pediatric and adult patients, as well as novel investigational agents. Finally, we explore emerging targeted therapies for rarer oncogenic drivers, such as FGFR and NTRK alterations, emphasizing the need for CNS-specific drug development strategies.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473324"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144037018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating B-ALL in the Era of Blinatumomab.","authors":"Sue Zupanec, Melissa Beauchemin, Rachel E Rau","doi":"10.1200/EDBK-25-472778","DOIUrl":"https://doi.org/10.1200/EDBK-25-472778","url":null,"abstract":"<p><p>Blinatumomab has rapidly emerged as a cornerstone in the treatment of B-cell ALL (B-ALL) across age and risk groups. Initially approved for minimal residual disease (MRD)-positive adult B-ALL in 2018, its indications have since expanded after pivotal trials demonstrating significant efficacy. The BLAST and E1910 trials highlighted the benefit of blinatumomab in adults in MRD-positive and MRD-negative remission, respectively, with notable improvements in overall survival and relapse-free survival. In pediatric populations, studies such as the AALL1731 and a landmark trial in infants with <i>KMT2A</i>-rearranged B-ALL demonstrated striking reductions in relapse when blinatumomab was added to standard regimens. Similarly, in Philadelphia chromosome-positive B-ALL, blinatumomab-based regimens have enabled chemotherapy minimization while achieving durable remissions. Despite these advances, the rapid integration of blinatumomab into standard care poses challenges related to administration, toxicity management, and equitable access. Variability in inpatient observation durations, infusion bag sizes, home health availability, and handling of infusion-related complications underscore the need for standardized delivery models. Additionally, low-grade and long-term toxicities-such as neurotoxicity, cytokine release syndrome, and hypogammaglobulinemia-remain undercharacterized. Looking forward, research is focusing on optimizing the use of blinatumomab, including its integration into reduced-intensity or chemotherapy-free regimens, alternative dosing schedules, and subcutaneous administration. As clinical use expands, emphasis must shift toward developing equitable, patient-centered delivery strategies and understanding the full spectrum of toxicities to ensure optimal and accessible care for all patients with B-ALL.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e472778"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144175116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Practical Guide to Clinical Trial Accessibility: Making Trial Participation a Standard of Care.","authors":"Hedyeh Ebrahimi, Jodie Allen, Yelak Biru, Ravin Garg, Christine Hodgdon, William K Oh, David Steensma, Sumanta K Pal, Therese Mulvey","doi":"10.1200/EDBK-25-100052","DOIUrl":"https://doi.org/10.1200/EDBK-25-100052","url":null,"abstract":"<p><p>Despite being a cornerstone of cancer treatment advancement, clinical trials remain inaccessible for many patients because of structural, socioeconomic, and systemic barriers. In this multidisciplinary perspective piece, stakeholders from patient advocacy, community oncology, industry, and academic medicine offer a collaborative overview of key challenges and practical solutions to improve trial accessibility. Patient advocates highlight the need to address language barriers, financial toxicity, and underrepresentation through community engagement and patient-centered trial design. Community oncologists underscore infrastructure limitations, generalist practice burdens, and misaligned trial offerings, calling for eligibility reform and cooperative trial models. Industry partners examine how overly restrictive criteria and inconsistent protocol practices hinder diversity and propose portfolio-wide strategies, such as protocol watch lists, for inclusive design. Academic oncologists focus on trial complexity, investigator burden, and limited generalizability, advocating for pragmatic and decentralized trial paradigms. Together, these perspectives underscore the shared responsibility across sectors to modernize clinical trial design, reduce access barriers, and ensure that trial participation becomes a standard and equitable component of cancer care.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e100052"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Addressing Barriers in Palliative Care for Rural and Underserved Communities.","authors":"Matthias Weiss, Susan Sabo-Wagner, Julia Frydman, C S Pramesh","doi":"10.1200/EDBK-25-472842","DOIUrl":"https://doi.org/10.1200/EDBK-25-472842","url":null,"abstract":"<p><p>Thirty-two million Americans live in rural counties and have no access to multidisciplinary cancer care, and patients with cancer describe a greater number of unfavorable social determinants of health (SDoH), experience more serious financial hardship as well as greater symptom burden, and are more likely to die of cancer. Delivering effective symptom management may be achieved through adoption of a <i>hub and spoke model</i>, which connects rural community care sites with a cancer center. Modern technologies (electronic medical record and virtual telehealth), advanced practice provider care models, and engagement in symptom management clinical trials can extend more optimal care to connected rural sites. Pragmatic examples of addressing these care barriers include systematic and proactive assessment of SDoH, supported by navigation and social services, and telehealth-enabled palliative care (PC). In low- and middle-income countries, access to supportive cancer care services is very limited, especially in rural areas. Digital health interventions, primarily limited to apps, and community health workers (trained volunteer care providers) have successfully enabled vital symptom management services. Access to PC, considered a basic human right, is unfortunately not available in many parts of the world, especially in rural areas of not only low- and middle-income but also high-income countries. Multiple approaches to deliver effective symptom management have been described but need to be tailored to the respective local health care infrastructure, resources, culture, and social, economic, and political environment.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e472842"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in the Clinic: Creating Harmony or Just Adding Noise?","authors":"Mariam Afzal, Katy E French, Larry E Bilbrey, Adeel A Faruki","doi":"10.1200/EDBK-25-481490","DOIUrl":"https://doi.org/10.1200/EDBK-25-481490","url":null,"abstract":"<p><p>Although still limited, the integration of artificial intelligence (AI) in health care has rapidly expanded in the past few years, especially in oncology clinics. In this article, AI refers to the development and implementation of computer systems capable of performing tasks that typically require human intelligence, such as language understanding, learning, and reasoning. AI technology is currently being used as <i>ambient listening technology</i> (AI-driven systems that passively capture verbal interactions between patients and health care providers), <i>patient messaging chatbots</i> (AI-enabled conversational agents designed to interact with patients by text or voice platforms), and as tools for inbox management and patient care delivery. However, the question remains: Is AI truly fostering harmony in health care, or just adding noise to an already complex system? Although the current applications of this technology have shown promising results in affecting routine care provided by physicians, this article will focus on AI's broader impact on the health care system-highlighting how ambient listening technology can improve the clinical experience for both patients and physicians, whether AI can reduce physician burnout through minimizing <i>in-basket workload</i> (the volume of messages that clinicians must manage within the electronic health record system), and AI's usage as a diagnostic tool. Key concerns addressed in this article include the potential pitfalls associated with AI integration, such as the need for proper clinician training to optimize AI algorithms while ensuring patient safety. The ambiguities surrounding the disclosure of AI in health care and the lack of a legal framework also raise significant concerns regarding patient autonomy, data privacy, trust, and beneficence. Future directions of AI in addressing these challenges are explored, alongside its potential integration into overburdened hospitals, underserved communities, telemedicine, and rural health care settings.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e481490"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Navigating First-Line Treatment Options for Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.","authors":"Giulia La Cava, Alessio Cortellini, Julia K Rotow, Jessica R Bauman","doi":"10.1200/EDBK-25-472784","DOIUrl":"https://doi.org/10.1200/EDBK-25-472784","url":null,"abstract":"<p><p>The discovery of epidermal growth factor receptor (<i>EGFR</i>) mutations in non-small cell lung cancer (NSCLC) and the subsequent development of targeted therapeutics represents a groundbreaking advancement in care, shifting the treatment paradigm to more personalized approaches with significantly improved survival because of our evolving understanding of the pathobiology and molecular underpinnings of the disease. First-line regimens for patients with <i>EGFR</i>-positive NSCLC now include EGFR tyrosine kinase inhibitor monotherapy or combination therapy with osimertinib and chemotherapy or amivantamab and lazertinib. There are several pros and cons to each approach of monotherapy vs combination therapy such that we must carefully weigh the balance between efficacy, toxicity, quality of life, and subsequent treatment options with our patients to determine the best approach at diagnosis of advanced disease. Importantly, there are subpopulations of patients who may benefit more from combination therapy, including those with <i>TP53</i> comutations, high tumor burden, brain metastases, and/or detectable ctDNA. This review discusses current data and treatment approaches for the management of advanced/metastatic <i>EGFR</i>-mutant NSCLC, with a particular emphasis on the complexity of first-line management.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e472784"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144188212","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor-Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas.","authors":"Rana R McKay, Renu Eapen, Elizabeth M Wulff-Burchfield, Michael S Hofman","doi":"10.1200/EDBK-25-473862","DOIUrl":"https://doi.org/10.1200/EDBK-25-473862","url":null,"abstract":"<p><p>Novel approaches in molecular imaging and targeted therapeutics are transforming the management of renal cell carcinoma (RCC) and urothelial carcinoma (UC). This review focuses on three key areas of innovation: molecular imaging, hypoxia-inducible factor-2α (HIF-2α) inhibition, and antibody-drug conjugates (ADCs). In molecular imaging, prostate-specific membrane antigen positron emission tomography/computed tomography has shown promise in RCC, while novel tracers targeting carbonic anhydrase IX and nectin-4 are emerging for RCC and UC, respectively. These approaches may enable better characterization of disease and treatment response monitoring. HIF-2α inhibition represents a breakthrough in targeting the fundamental pathobiology of clear cell RCC, with belzutifan demonstrating significant clinical benefit in both von Hippel-Lindau disease and sporadic RCC. Next-generation HIF-2α inhibitors, including casdatifan, show promising early clinical results with distinct pharmacologic properties. ADCs have become a cornerstone of UC treatment, with enfortumab vedotin plus pembrolizumab now approved as first-line therapy. Multiple human epidermal growth factor receptor 2 (HER2)-directed ADCs have shown efficacy in HER2-expressing UC, including trastuzumab deruxtecan, which recently received tumor-agnostic approval. While ADC development in RCC faces unique challenges, novel approaches including immunostimulatory payloads and bispecific antibodies are being explored. The integration of these advances in molecular imaging and therapeutics offers opportunities for more personalized treatment approaches in RCC and UC.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473862"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143812537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liquid Biopsy Approaches for Cancer Characterization, Residual Disease Detection, and Therapy Monitoring.","authors":"Jacqueline V Aredo, Amna Jamali, Jessica Zhu, Natalie Heater, Heather A Wakelee, Christos Vaklavas, Valsamo Anagnostou, Janice Lu","doi":"10.1200/EDBK-25-481114","DOIUrl":"https://doi.org/10.1200/EDBK-25-481114","url":null,"abstract":"<p><p>Liquid biopsy encompasses a variety of molecular approaches to detect circulating tumor DNA (ctDNA) and has become a powerful tool in the diagnosis and treatment of solid tumors. Current applications include comprehensive genomic profiling for identifying targetable mutations and therapeutic resistance mechanisms, with emerging applications in minimal residual disease detection and treatment response monitoring. Increasingly, the potential for liquid biopsy in guiding treatment decisions is under active investigation through prospective clinical trials using ctDNA-adaptive interventions in patients with early-stage and metastatic cancers. Limitations arise on the basis of the sensitivity and feasibility of individual liquid biopsy assays; nonetheless, emerging technologies set the stage for improving these shortcomings. As the global oncology community continues to ascertain the clinical value of liquid biopsy across the continuum of patient care, this minimally invasive approach heralds a significant advancement in the promise of precision oncology.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e481114"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144051464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Older Patients With ALL.","authors":"Elias Jabbour, Fadi G Haddad, Hagop Kantarjian","doi":"10.1200/EDBK-25-473298","DOIUrl":"https://doi.org/10.1200/EDBK-25-473298","url":null,"abstract":"<p><p>Older patients with ALL often have high-risk disease characterized by adverse-risk cytogenetic and molecular abnormalities, as well as Philadelphia chromosome (Ph)-positive and Ph-like phenotypes. They often have comorbidities resulting in poor tolerance to chemotherapy and are at risk of developing therapy-related myeloid neoplasms (t-MNs). In Ph-negative ALL, the duration and intensity of chemotherapy was reduced, and outcomes improved with the addition of inotuzumab ozogamicin (InO) and blinatumomab into the frontline setting. However, t-MNs are still being observed, prompting the development of chemotherapy-free regimens with InO and blinatumomab as well as chimeric antigen receptor (CAR) T-cell therapies in high-risk disease. In Ph-positive ALL, chemotherapy and allogeneic hematopoietic stem-cell transplantation (HSCT) were historically considered a standard of care. However, the introduction of blinatumomab and newer-generation BCR::ABL1 tyrosine kinase inhibitors (TKIs) into the frontline setting significantly improved outcomes. The combination of blinatumomab and ponatinib induced high rates of complete molecular responses and excellent survival, without reliance on HSCT. A subset of patients with elevated WBC count at diagnosis are at particular risk of CNS and systemic relapse and may require additional strategies such as incorporating one to two cycles of high-dose methotrexate/cytarabine into consolidation, and potentially CAR T cells. In T-cell ALL, adding venetoclax into the frontline setting has improved outcomes. In early T-cell precursor ALL, HSCT is still needed. To further improve outcomes in older patients, novel agents such as subcutaneous blinatumomab, CAR T cells, newer-generation TKIs, and menin inhibitors should be investigated in the frontline setting.</p>","PeriodicalId":37969,"journal":{"name":"American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting","volume":"45 3","pages":"e473298"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}